Long-term management of gastroesophageal reflux disease with pantoprazole

References

• AchimARiddermannTPfaffenbergerBPantoprazole 40 mg is at least comparable to esomeprazole 40 mg in achieving endoscopically confirmed healing and symptom relief of gastroesophageal reflux disease (GERD) after 4, 8 and 12 weeks of treatmentCan J Gastroenterol200519Suppl C DR.0038
   Google Scholar
• AdamekRJBehrendtJWenzelCRelapse prevention in reflux oesophagitis with regard to Helicobacter pylori status: a double-blind, randomized, multicentre trial to compare the efficacy of pantoprazole versus ranitidineEur J Gastroenterol Hepatol2001138111711474311
   PubMedGoogle Scholar
• ArangoLAngelAMolinaRIComparison between digestive endoscopy and 24-hour esophageal pH monitoring for the diagnosis of gastroesophageal reflux esophagitis: “presentation of 100 cases.Hepatogastroenterology2000471748010690605
   PubMedGoogle Scholar
• ArnoldRSafety of proton pump inhibitors—an overviewAliment Pharmacol Ther1994865708180297
   PubMedGoogle Scholar
• BacakBSPatelMTweedEWhat is the best way to manage GERD symptoms in the elderly?J Fam Pract2006552514,816510061
   PubMedGoogle Scholar
• BardhanKDIntermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux diseaseAm J Gastroenterol200398S40812644030
   PubMedGoogle Scholar
• BardhanKDCherianPBishopAEPantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studiesAm J Gastroenterol20019617677611419827
   PubMed Web of Science ®Google Scholar
• BellNJHuntRHProgress with proton pump inhibitionYale J Biol Med19926564957 discussion 89–921341069
   PubMed Web of Science ®Google Scholar
• BloomBSJayadevappaRWahlPTime trends in cost of caring for people with gastroesophageal reflux diseaseAm J Gastroenterol200196S64911510775
   PubMedGoogle Scholar
• BlumeHDonathFWarnkeAPharmacokinetic drug interaction profiles of proton pump inhibitorsDrug Safety2006297698416944963
   PubMed Web of Science ®Google Scholar
• BochenekWJMackMEFragaPDPantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitisAliment Pharmacol Ther20042011051415569113
   PubMedGoogle Scholar
• BollschweilerEWolfgartenEGutschowCDemographic variations in the rising incidence of esophageal adenocarcinoma in white malesCancer2001925495511505399
   PubMed Web of Science ®Google Scholar
• CarlssonRDentJWattsRGastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study GroupEur J Gastroenterol Hepatol199810119249581986
   PubMed Web of Science ®Google Scholar
• CaroJJSalasMWardAHealing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trialsClin Ther200123998101711519776
   PubMed Web of Science ®Google Scholar
• CheerSMPrakashAFauldsDPantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disordersDrugs2003631013312487624
   PubMed Web of Science ®Google Scholar
• ChibaNProton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overviewCan J Gastroenterol199711Suppl B66B73B
   PubMedGoogle Scholar
• ChibaNDe GaraCJWilkinsonJMSpeed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysisGastroenterology199711217988109178669
   PubMed Web of Science ®Google Scholar
• CrawleyJAMaclin SchmittCHow satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs surveyJ Clin Outcomes Manag200072934
   Google Scholar
• CsendesASmokGCerdaGPrevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett’s esophagusDis Esophagus19971038429079272
   PubMedGoogle Scholar
• DajaniEZGastroesophageal reflux disease: pathophysiology and pharmacology overviewJ Assoc Acad Minor Phys20001171110826019
   PubMedGoogle Scholar
• DentJBrunJFendrickAAn evidence-based appraisal of reflux disease management—the Genval Workshop reportGut199944S1S1610741335
   PubMed Web of Science ®Google Scholar
• de-Souza-CuryMFerrariAPCiconelliREvaluation of health-related quality of life in gastroesophageal reflux disease patients before and after treatment with pantoprazoleDiseases of the Esophagus2006192899316866863
   PubMedGoogle Scholar
• DeVaultKLynnRBochenekWSuccessful treatment of elderly patients with erosive esophagitis (EE) using pantoprazole 40 mgAm J Gastroenterol2003SepSuppl.S3
   PubMedGoogle Scholar
• DeVaultKRCastellDOUpdated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of GastroenterologyAm J Gastroenterol19999414344210364004
   PubMed Web of Science ®Google Scholar
• DeVaultKMalageladaJHoltmannGGERDyzer™ treatment satisfaction module: correlation with symptom assessment by ReQuest™—GI (abstract)Am J Gastroenterol2006101Suppl. 2S400
   Google Scholar
• DimenasECarlssonGGliseHRelevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal diseaseScand J Gastroenterol Suppl19962218139110389
   PubMedGoogle Scholar
• DimenasEGliseHHallerbackBQuality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?Scand J Gastroenterol19932868178210982
   PubMed Web of Science ®Google Scholar
• DonnellanCSharmaNPrestonCMedical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux diseaseCochrane Database Syst Rev20044CD003245
   Google Scholar
• El-SeragHBSonnenbergAAssociations between different forms of gastro-oesophageal reflux diseaseGut19974159499414963
   PubMed Web of Science ®Google Scholar
• EnckPDuboisDMarquisPQuality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST)Scand J Gastroenterol Suppl1999231485410565623
   PubMedGoogle Scholar
• EscourrouJDeprezPSaggioroAMaintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitisAliment Pharmacol Ther19991314819110571605
   PubMed Web of Science ®Google Scholar
• FarupCKleinmanLSloanSThe impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of lifeArch Intern Med2001a161455211146697
   PubMed Web of Science ®Google Scholar
• FarupCKleinmanLSloanSThe impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of lifeArch Intern Med2001b161455211146697
   PubMed Web of Science ®Google Scholar
• FassROfmanJJGralnekIMClinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux diseaseArch Intern Med19991592161810527293
   PubMed Web of Science ®Google Scholar
• FassROfmanJJSamplinerREThe omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitisAliment Pharmacol Ther2000143899610759617
   PubMed Web of Science ®Google Scholar
• FendrickAMManagement of patients with symptomatic gastroesophageal reflux disease: a primary care perspectiveAm J Gastroenterol200196S293311510767
   PubMedGoogle Scholar
• FennertyMBZuckermanSSpreenKAHeartburn severity does not predict disease severity in gastroesophageal reflux patients with erosive esophagitis2002Las Vegas, NVAmerican Osteopathic Association
   Google Scholar
• FrestonJWLong-term acid control and proton pump inhibitors: interactions and safety issues in perspectiveAm J Gastroenterol19979251S5S discussion 5S–7S9127627
   PubMedGoogle Scholar
• GillessenABeilWModlinIM40 mg pantoprazole and 40 mg esomeprazole are equivalent in the healing of esophageal lesions and relief from gastroesophageal reflux disease-related symptomsJ Clin Gastroenterol2004383324015087692
   PubMed Web of Science ®Google Scholar
• GlatzelDAbdel-QaderMGatzGPantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease (GERD) after 4 weeks of treatment and superior regarding prevention of symptomatic relapseDigestion2006741455417230024
   PubMedGoogle Scholar
• GohKWuCBenamouzigRSanderPEfficacy of Pantoprazole 20 mg daily compared to Esomeprazole 20 mg daily in the maintenance of gastroesophageal reflux disease: a randomized, double-blind comparative trial: the EMANCIPATE studyEuro J Gastro Hepatol20071920511
   PubMed Web of Science ®Google Scholar
• GorardDAEscalating polypharmacyQJM20069979780017030528
   PubMed Web of Science ®Google Scholar
• GreenJIs there such an entity as mild oesophagitis?Eur J Clin Res199342934
   Google Scholar
• HaagSHoltmannGReflux disease and Barrett’s esophagusEndoscopy2003351121712561004
   PubMedGoogle Scholar
• HabermannWKieslerKEhererAShort-term therapeutic trial of proton pump inhibitors in suspected extraesophageal refluxJ Voice2002164253212395996
   PubMed Web of Science ®Google Scholar
• HalsteadLAExtraesophageal manifestations of GERD: diagnosis and therapyDrugs Today (Barc)200541Suppl B192616200228
   PubMedGoogle Scholar
• HeinzeHPreinfalkJAthmannCClinical efficacy and safety of pantoprazole in severe acid-peptic disease during up to 10 years maintenance treatmentGut200352Suppl. VIA63
   PubMedGoogle Scholar
• HenkeCJLevinTRHenningJMWork loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organizationAm J Gastroenterol2000957889210710076
   PubMed Web of Science ®Google Scholar
• HetzelDJDentJReedWDHealing and relapse of severe peptic esophagitis after treatment with omeprazoleGastroenterology198895903123044912
   PubMed Web of Science ®Google Scholar
• HollenzMStolteMLabenzJPrevalence of gastro-oesophageal reflux disease in general practiceDeutsche Medizinische Wochenschrift200212710071211997867
   PubMedGoogle Scholar
• HoltmannGChassanyODeVaultKGERDyzer™: validation of a new scale for the assessment of health related quality of life in gastroesophageal reflux disease (GERD) [abstract]Gut200554Suppl. VIIA52
   Google Scholar
• HoltmannGDeVaultKChassanyOFast onset of action: the initial dose of pantoprazole is superior to esomeprazole in reducing the frequence and intensity of acid episodes determined by ReQuest™ [abstract]Gut2006a55Suppl. VA271
   Google Scholar
• HoltmannGMalageladaJChassanyOGender and age influence health-related quality of life (HRQoL) in GERD: patients assessed by GERDyzerTM [abstract]Gut2006b55Suppl VA269
   Google Scholar
• HolzerSSJudayTRJoelssonBDetermining the cost of gastroesophageal reflux disease: a decision analytic modelAm J Manag Care1998414506010338737
   PubMed Web of Science ®Google Scholar
• JohanssonKEAskPBoerydBOesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastrooesophageal reflux diseaseScand J Gastroenterol198621837473775250
   PubMed Web of Science ®Google Scholar
• JohnsonDAEndoscopic therapy for GERD—baking, sewing, or stuffing: an evidence-based perspectiveRev Gastroenterol Disord20033142914502118
   PubMedGoogle Scholar
• JohnsonDAFennertyMBHeartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux diseaseGastroenterology2004126660414988819
   PubMed Web of Science ®Google Scholar
• KahrilasPJFennertyMBJoelssonBHigh- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trialAm J Gastroenterol1999949279934737
   PubMed Web of Science ®Google Scholar
• Kaplan-MachlisBSpieglerGERevickiDAHealth-related quality of life in primary care patients with gastroesophageal reflux diseaseAnn Pharmacother1999331032610534213
   PubMedGoogle Scholar
• KaspariSBiedermannAMeyJComparison of pantoprazole 20 mg to ranitidine 150 mg bid in the treatment of mild gastroesophageal reflux diseaseDigestion2001631637011351143
   PubMedGoogle Scholar
• KaspariSKupcinskasLHeinzeHPantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux diseaseEur J Gastroenterol Hepatol2005179354116093871
   PubMed Web of Science ®Google Scholar
• KuligMLeodolterAViethMQuality of life in relation to symptoms in patients with gastro-oesophageal reflux disease—an analysis based on the ProGERD initiativeAliment Pharmacol Ther2003187677614535869
   PubMed Web of Science ®Google Scholar
• LabenzJArmstrongDLauritsenKEsomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO studyAliment Pharmacol Ther2005228031116225489
   PubMed Web of Science ®Google Scholar
• LabenzJMalfertheinerPHelicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?Gut199741277809378377
   PubMed Web of Science ®Google Scholar
• LabenzJPetersenKURoschWA summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazoleAliment Pharmacol Ther20031710151912694083
   PubMed Web of Science ®Google Scholar
• LagergrenJBergströmRLindgrenASymptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinomaN Engl J Med19993408253110080844
   PubMed Web of Science ®Google Scholar
• LassenAHallasJde MuckadellOBEsophagitis: incidence and risk of esophageal adenocarcinoma—a population-based cohort studyAm J Gastroenterol20061011193916771936
   PubMed Web of Science ®Google Scholar
• LauritsenKDevièreJBigardMAEsomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study resultsAm J Gastroenterol20031719
   Google Scholar
• LauritsenKJaupBCarlingLComparable efficacy of pantoprazole and omeprazole to prevent relapse in patients with GERD [abstract]Gut200047Suppl. IIIA60
   Google Scholar
• LundellLMiettinenPMyrvoldHELong-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study GroupEur J Gastroenterol Hepatol2000128798710958215
   PubMed Web of Science ®Google Scholar
• Madrazo-De la GarzaADibildoxMVargasAEfficacy and safety of oral pantoprazole 20 mg given once daily for reflux esophagitis in childrenJ Pediatr Gastroenterol Nutr200336261512548064
   PubMed Web of Science ®Google Scholar
• MaekawaTKinoshitaYOkadaARelationship between severity and symptoms of reflux oesophagitis in elderly patients in JapanJ Gastroenterol Hepatol199813927309794192
   PubMedGoogle Scholar
• MalageladaJChassanyODeVaultKHealth-related quality of life (HRQoL) in GERD patients is significantly infl uenced by gastrointestinal symptoms [abstract]Gut200655Suppl. VA253
   Google Scholar
• McDougallNIJohnstonBTKeeFNatural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of lifeGut19963848168707073
   PubMed Web of Science ®Google Scholar
• MetzDCBochenekWJPantoprazole maintenance therapy prevents relapse of erosive oesophagitisAliment Pharmacol Ther2003171556412492745
   PubMed Web of Science ®Google Scholar
• MoldJWReedLEDavisABPrevalence of gastroesophageal reflux in elderly patients in a primary care settingAm J Gastroenterol199186965701858762
   PubMed Web of Science ®Google Scholar
• MossnerJKoopHPorstHOne-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux symptoms in patients with healed reflux oesophagitisAliment Pharmacol Ther1997111087929663834
   PubMed Web of Science ®Google Scholar
• MulderCJWesterveldBDSmitJMA double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trialEur J Gastroenterol Hepatol2002146495612072599
   PubMed Web of Science ®Google Scholar
• MyrvoldHELundellLMiettinenPThe cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgeryGut2001494889411559644
   PubMed Web of Science ®Google Scholar
• NetzerPBrabetz-HofligerABrundlerRComparison of the effect of the antacid Rennie versus low-dose H2-receptor antagonists (ranitidine, famotidine) on intragastric acidityAliment Pharmacol Ther199812337429690722
   PubMed Web of Science ®Google Scholar
• NumansMELauJde WitNJShort-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristicsAnn Intern Med20041405182715068979
   PubMed Web of Science ®Google Scholar
• NwokoloCUSmithJTGaveyCTolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidineAliment Pharmacol Ther19904Suppl 129451983345
   PubMed Web of Science ®Google Scholar
• OrlandoRYamadaTAlpersDReflux esophagitisTextbook of gastroenterology1999PhiladelphiaLippincott Williams & Wilkins123563
   Google Scholar
• OrlandoRCThe pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposureAm J Gastroenterol1997923S5S discussion S–7S9127620
   PubMedGoogle Scholar
• OrlandoRCCurrent understanding of the mechanisms of gastrooesophageal reflux diseaseDrugs200666Suppl 115 discussion 29–3316869342
   PubMed Web of Science ®Google Scholar
• ParePArmstrongDPericakDPantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidineJ Clin Gastroenterol200337132812869883
   PubMed Web of Science ®Google Scholar
• PilottoAFranceschiMPilottoAMalfertheinerPHoltPGastro-esophageal reflux disease in the elderlyAging and the gastrointestinal tract. Interdisciplinary topics in gerontology2003BaselKarger Press10017
   Google Scholar
• PilottoAFranceschiMParisFRecent advances in the treatment of GERD in the elderly: focus on proton pump inhibitorsInt J Clin Pract2005591204916178989
   PubMed Web of Science ®Google Scholar
• PilottoALeandroGFranceschiMShort- and long-term therapy for reflux oesophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazoleAliment Pharmacol Ther200317139940612786634
   PubMed Web of Science ®Google Scholar
• PleinKHotzJWurzerHPantoprazole 20 mg is an effective maintenance therapy for patients with gastro-oesophageal reflux diseaseEur J Gastroenterol Hepatol2000124253210783996
   PubMed Web of Science ®Google Scholar
• PrasadMRentzAMRevickiDAThe impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature reviewPharmacoeconomics2003217699012859219
   PubMed Web of Science ®Google Scholar
• RaghunathAHunginAPWooffDPrevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic reviewBMJ200332673712676842
   PubMed Web of Science ®Google Scholar
• RaiAOrlandoRGastroesophageal reflux diseaseCur Opin Gastroenterol19981432633
   Google Scholar
• RäihäIHietanenESouranderLSymptoms of gastro-oesophageal reflux disease in elderly peopleAge Ageing199120365701755393
   PubMedGoogle Scholar
• RevickiDACrawleyJAZodetMWComplete resolution of heartburn symptoms and health-related quality of life in patients with gastrooesophageal reflux diseaseAliment Pharmacol Ther19991316213010594397
   PubMed Web of Science ®Google Scholar
• RevickiDAWoodMMatonPNThe impact of gastroesophageal reflux disease on health-related quality of lifeAm J Med199810425289552088
   PubMed Web of Science ®Google Scholar
• RichterJEGastroesophageal reflux disease in the older patient: presentation, treatment, and complicationsAm J Gastroenterol2000953687310685737
   PubMed Web of Science ®Google Scholar
• RichterJEBochenekWOral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study GroupAm J Gastroenterol20009530718011095320
   PubMed Web of Science ®Google Scholar
• RichterJEFragaPMackMPrevention of erosive oesophagitis relapse with pantoprazoleAliment Pharmacol Ther2004205677515339328
   PubMed Web of Science ®Google Scholar
• RobinsonMHornJClinical pharmacology of proton pump inhibitors: what the practising physician needs to knowDrugs20036327395414664653
   PubMed Web of Science ®Google Scholar
• RuigomezAGarcia RodriguezLAWallanderMANatural history of gastro-oesophageal reflux disease diagnosed in general practiceAliment Pharmacol Ther2004207516015379835
   PubMed Web of Science ®Google Scholar
• SachsGProton pump inhibitors and acid-related diseasesPharmacotherapy19971722379017763
   PubMed Web of Science ®Google Scholar
• SandlerRSEverhartJEDonowitzMThe burden of selected digestive diseases in the United StatesGastroenterology200212215001111984534
   PubMed Web of Science ®Google Scholar
• ScholtenTBohuschkeMGatzGOn-demand therapy with pantoprazole 20 mg leads to lower heartburn intensity than with esomeprazole 20 mg in patients with mild GERDGut200554Suppl. VIIA109
   Google Scholar
• ScholtenTDekkersCPSchutzeKOn-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trialDigestion200572768516113546
   PubMed Web of Science ®Google Scholar
• ScholtenTGatzGHoleUOnce-daily pantoprazole 40 mg and esomeprazole 40 mg have equivalent overall efficacy in relieving GERD-related symptomsAliment Pharmacol Ther2003185879412969085
   PubMed Web of Science ®Google Scholar
• ShakerRCastellDOSchoenfeldPSNighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological AssociationAm J Gastroenterol20039814879312873567
   PubMed Web of Science ®Google Scholar
• SharmaPVakilNReview article: Helicobacter pylori and reflux diseaseAliment Pharmacol Ther20031729730512562442
   PubMedGoogle Scholar
• ShawMJFendrickAMKaneRLSelf-reported effectiveness and physician consultation rate in users of over-the-counter histamine-2 receptor antagonistsAm J Gastroenterol200196673611280532
   PubMed Web of Science ®Google Scholar
• SontagSJSonnenbergASchnellTGThe long-term natural history of gastroesophageal reflux diseaseJ Clin Gastroenterol20064039840416721220
   PubMed Web of Science ®Google Scholar
• SpechlerSJGoyalRKBarrett’s esophagusN Engl J Med1986315362712874485
   PubMed Web of Science ®Google Scholar
• SpechlerSJLeeEAhnenDLong-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trialJAMA20012852331811343480
   PubMed Web of Science ®Google Scholar
• StanghelliniVArmstrongDMonnikesHDetermination of ReQuest-based symptom thresholds to define symptom relief in GERD clinical studiesDigestion2005711455115870502
   PubMed Web of Science ®Google Scholar
• SteinmanMALandefeldCSRosenthalGEPolypharmacy and prescribing quality in older peopleJ Am Geriatr Soc20065415162317038068
   PubMed Web of Science ®Google Scholar
• TeferaLFeinMRitterMPCan the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease?Am Surg19976393369322676
   PubMedGoogle Scholar
• ToliaVBishopPTsouVMulticenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5–11 years) with symptomatic gastroesophageal reflux diseaseJ Pediatr Gastroenterol Nutr2006423849116641576
   PubMed Web of Science ®Google Scholar
• TsouVBakerRBookLMulticenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD)Clin Pediatr2006457419
   PubMed Web of Science ®Google Scholar
• VakilNShawMKirbyRClinical effectiveness of laparoscopic fundoplication in a U.S. communityAm J Med20031141512543281
   PubMed Web of Science ®Google Scholar
• VakilNvan ZantenSVKahrilasPThe Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensusAm J Gastroenterol200610119002016928254
   PubMed Web of Science ®Google Scholar
• Van HerwaardenMASamsomMSmoutAJExcess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxationsGastroenterology200011914394611113064
   PubMed Web of Science ®Google Scholar
• van HoutBAKlokRMBrouwersJRA pharmacoeconomic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The NetherlandsClin Ther2003256354612749518
   PubMedGoogle Scholar
• van RensburgCJHoniballPJGrundlingHDEfficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitisAliment Pharmacol Ther1996103974018791969
   PubMed Web of Science ®Google Scholar
• Van RensburgCJHoniballPJVan ZylJHSafety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis-a 2-year follow-upAliment Pharmacol Ther1999131023810468676
   PubMed Web of Science ®Google Scholar
• WatsonDIJamiesonGGBaigrieRJLaparoscopic surgery for gastro-oesophageal reflux: beyond the learning curveBr J Surg199683128478983630
   PubMed Web of Science ®Google Scholar
• WelageLSBerardiRREvaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseasesJ Am Pharm Assoc (Wash)2000405262 quiz 121–310665250
   PubMedGoogle Scholar
• WiklundIBardhanKDMuller-LissnerSQuality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre clinical trial. The European Study GroupItal J Gastroenterol Hepatol19983019279615259
   PubMedGoogle Scholar
• WyethJWPounderRESercombeJCThe effects of low doses of ranitidine on intragastric acidity in healthy menAliment Pharmacol Ther199812255619570260
   PubMedGoogle Scholar
• ZimmermanJShohatVTsvangEEsophagitis is a major cause of upper gastrointestinal hemorrhage in the elderlyScand J Gastroenterol19973290699299669
   PubMed Web of Science ®Google Scholar